[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"prostatic-neoplasm\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:prostatic-neoplasm":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,8,0,[8,47,99,126,164,186,223,247],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":30,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100599460","investigation-of-impact-of-ai-on-prostate-cancer-workflow-100599460",false,"NCT07084779","Investigation of Impact of AI on Prostate Cancer Workflow","Inclusion Criteria:\n\n* Plan of care is to undergo a biopsy of the prostate after a pre-biopsy MRI\n* Age 55-80\n* Prostate-specific antigen (PSA) between 3-10 ng\u002FmL\n* No prior diagnosis or treatment of prostate cancer\n\nExclusion Criteria:\n\n* Pre-biopsy MRI is of low quality\n* PI-QUAL score of 1 using PI-QUAL version 2","ALL","55 Years","80 Years",{"count":19,"type":20},150,"ESTIMATED","INTERVENTIONAL",[23],"NA","This study will enroll participants who are undergoing an MRI before a prostate biopsy due to suspected prostate cancer. The purpose of this study is to see if the use of Artificial Intelligence (AI) helps detect lesions on an MRI better than a radiologist not using AI. The AI Rad Companion (AIRC) Prostate MRI application is a software that uses measurements of the prostate and will be utilized in this study to help detect potential cancerous lesions. The AI software will assign the lesions a PI-RADS score, which is a way to measure the chance of the lesion being cancer.\n\nThere are two parts to this study. The first part involves comparing the interpretation of prostate MRI images by a radiologist alone, a radiologist aided by AI, and AI alone. A systematic biopsy will be completed per standard of care. The radiologist may opt to include up to 2 additional AI-identified targets to biopsy in addition to those biopsied for standard of care.\n\nThe second part of the study involves utilizing the MRI images from the first part of the study in addition to retrospective prostate MRI images. These de-identified images, along with Prostate Image Quality (PI-QUAL) scores, clinical data, and biopsy results will be sent to Siemens in order to aid in the development of methods to identify good or bad image quality in prostate MRI images.",[26,27,28,29],"Prostate Cancer","Prostatic Neoplasm","Cancer of the Prostate","Neoplasms, Prostate",[31,32,33],"Artificial Intelligence","Magnetic Resonance Imaging","Biopsy","RECRUITING","2026-05-13",{"date":37,"type":38},"2026-05-15","ACTUAL",{"date":40,"type":38},"2025-09-09",{"date":42,"type":20},"2026-11-30",{"name":44,"class":45},"Case Comprehensive Cancer Center","OTHER",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":15,"minAge":55,"maxAge":4,"enrollmentInfo":56,"targetDuration":4,"studyType":21,"phases":58,"briefSummary":61,"conditions":62,"keywords":73,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":98},"100499704","phase-2-determine-trial-treatment-arm-04-trastuzumab-in-combination-with-pertuzumab-in-adult-paediatric-and-teenageyoung-adult-patients-with-cancers-with-her2-amplification-or-activating-mutations-100499704","NCT05786716","DETERMINE Trial Treatment Arm 04: Trastuzumab in Combination With Pertuzumab in Adult, Paediatric and Teenage\u002FYoung Adult Patients With Cancers With HER2 Amplification or Activating Mutations","DETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial): An Umbrella-Basket Platform Trial to Evaluate the Efficacy of Targeted Therapies in Rare Adult, Paediatric and Teenage\u002FYoung Adult (TYA) Cancers With Actionable Genomic Alterations, Including Common Cancers With Rare Actionable Alterations. Treatment Arm 04: Trastuzumab in Combination With Pertuzumab in Adult, Paediatric and Teenage\u002FYoung Adult Patients With Cancers With HER2 Amplification or Activating Mutations.","DETERMINE","THE PATIENT MUST FULFIL THE ELIGIBILITY CRITERIA WITHIN THE DETERMINE MASTER PROTOCOL (NCT05722886) AND WITHIN THE TREATMENT ARM 04 (TRASTUZUMAB AND PERTUZUMAB) OUTLINED BELOW\\*\n\n\\*When trastuzumab- and pertuzumab-specific inclusion\u002Fexclusion criteria or precautions below differ from those specified in the Master Protocol, the trastuzumab- and pertuzumab-specific criteria will take precedence.\n\nInclusion Criteria:\n\nA. Confirmed diagnosis of a malignancy harbouring HER2 amplification, or an appropriate activating mutation as defined by the MTB, using an analytically validated next-generation sequencing method.\n\n• A HER2 amplification copy number between 5-9 will require an MTB discussion. A HER2 amplification copy number ≥10 will be fast-tracked for an MTB recommendation, unless there are any patient-specific individualities (such as multiple gene amplifications) that require MTB discussion.\n\nB. Age 12 years or above.\n\nC. Women of childbearing potential are eligible provided that they meet the following criteria:\n\nHave a negative serum or urine pregnancy test before enrolment and;\n\nAgree to use one form of effective birth control method such as:\n\nI. combined (oestrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation (oral, intravaginal or transdermal):\n\nII. progestogen-only hormonal contraception associated with or without inhibition of ovulation (oral, injectable or implantable)\n\nIII. intrauterine device (IUD)\n\nIV. intrauterine hormone-releasing system (IUS)\n\nV. bilateral tubal occlusion\n\nVI. vasectomised partner\n\nVII. sexual abstinence\n\nVIII. male or female condom with or without spermicide\n\nIX. cap, diaphragm or sponge with spermicide\n\nEffective from the first administration of trastuzumab or pertuzumab (whichever is first), throughout the trial and for seven months after the last administration of trastuzumab or pertuzumab (whichever is later).\n\nD. Male patients with partners who are women of childbearing potential are eligible provided that they agree to the following, from the first administration of trastuzumab or pertuzumab (whichever is first), throughout the trial and for seven months after the last administration of trastuzumab or pertuzumab (whichever is later):\n\n* Agree to take measures not to father children by using a barrier method of contraception (condom plus spermicide) or to sexual abstinence.\n* Non-vasectomised male patients with partners who are women of childbearing potential must also be willing to ensure that their partner uses an effective method of contraception as in C, above.\n* Male patients with pregnant or lactating partners must be advised to use barrier method contraception (e.g. condom) to prevent drug exposure of the foetus or neonate.\n\nAll male patients must refrain from donating sperm for the same period.\n\nE. Patients must be able and willing to undergo a fresh tissue biopsy at baseline and blood samples for translational research. Note that for patients with haematological malignancies or neuroblastomas, blood, bone marrow aspiration and\u002For trephine or lymph node biopsy samples may be taken.\n\nF. ADULT PATIENTS (≥18 years): Adequate organ function as per haematological and biochemical indices within the ranges defined in the protocol. These measurements should be performed to confirm the patient's eligibility.\n\nG. PAEDIATRIC PATIENTS (\\\u003C18 years): Adequate organ function as per haematological and biochemical indices within the ranges defined in the protocol. These measurements should be performed to confirm the patient's eligibility.\n\nExclusion Criteria:\n\nA. Diagnosis of HER2-positive early or metastatic breast cancer.\n\nB. Female patients who are pregnant, breastfeeding or planning to become pregnant during the trial or within seven months following their last dose of trastuzumab or pertuzumab (whichever is later).\n\nC. Severe dyspnoea at rest due to complications of advanced malignancy or requiring supplementary oxygen therapy.\n\nD. Known hypersensitivity to trastuzumab or pertuzumab, murine proteins, or to any of the excipients.\n\nE. Patients who were administered a live, attenuated vaccine within 28 days prior to enrolment, or anticipation of need for such a vaccine during trastuzumab and pertuzumab treatment or within six months after the final dose of trastuzumab and pertuzumab.\n\nF. Patients with clinically significant pre-existing cardiac conditions, including uncontrolled or symptomatic angina, uncontrolled atrial or ventricular arrhythmias (within three months), NYHA class III or IV congestive heart failure.\n\nLeft Ventricular Ejection Fraction \\\u003C55%.\n\nPatients with a cerebrovascular event (including stroke or transient ischaemic attack \\[TIA\\]) or cardiovascular event (including acute myocardial infarction \\[MI\\]) within three months before the first dose of trastuzumab and pertuzumab.\n\n• Patients with primary CNS tumours may be considered unless intra-tumoural bleeding has occurred within 2 weeks of the first dose of trastuzumab and pertuzumab, and patients with punctate CNS haemorrhages \\\u003C3 mm may be considered.\n\nG. Prior treatment with the same class of drug unless genetic profile demonstrates a mechanism of resistance known to be potentially sensitive to trastuzumab or pertuzumab.\n\nH. Any clinically significant concomitant disease or condition (or its treatment) that could interfere with the conduct of the trial or absorption of oral medications or that would, in the opinion of the Investigator, pose an unacceptable risk to the patient in this trial.\n\nI. Known active infections (bacterial, fungal or viral) that would interfere with the assessment of safety or efficacy of trastuzumab and pertuzumab, including human immunodeficiency virus (HIV) positivity. Patients with history of testing positive for HIV infection are eligible provided the each of the following conditions are met:\n\n* CD4 count ≥350\u002FμL;\n* undetectable viral load;\n* receiving antiretroviral therapy (ART) that does not interact with IMP (patients should be on established ART for at least four weeks); and\n* no HIV\u002F acquired immune deficiency syndrome (AIDS)-associated opportunistic infection in the last 12 months.","12 Years",{"count":57,"type":20},30,[59,60],"PHASE2","PHASE3","This clinical trial is looking at a combination of drugs called trastuzumab and pertuzumab. This combination of drugs is approved together as standard of care treatment for adult patients with breast cancer (often with other anti-cancer drugs). This means it has gone through clinical trials and been approved by the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK.\n\nTrastuzumab and pertuzumab work in patients with these types of cancers which have a molecular alteration called HER2 amplification or HER2 activating mutation.\n\nInvestigators now wish to find out if it will be useful in treating patients with other cancer types which are also HER2 amplified or HER2 mutated. If the results are positive, the study team will work with the NHS and the Cancer Drugs Fund to see if these drugs can be routinely accessed for patients in the future.\n\nThis trial is part of a trial programme called DETERMINE. The programme will also look at other anti-cancer drugs in the same way, through matching the drug to rare cancer types or ones with specific mutations.",[63,64,65,66,67,68,69,70,27,71,72],"Haematological Malignancy","Colorectal Neoplasms","Urinary Bladder Neoplasm","Gallbladder Neoplasms","Salivary Gland Neoplasm","Lung Neoplasm","Pancreatic Neoplasm","Ovarian Neoplasms","Skin Neoplasm","Solid Tumour",[74,75,76,77,78,79,80,81,82,83,84,85,86,87,88],"Adult","Antibodies, monoclonal","Cancer","Child","Molecular Targeted Therapy","Mutation","Paediatric","Pertuzumab","Precision Medicine","Rare","Receptor, ErbB-2","Targeted","Trastuzumab","Tumour-agnostic","Young adult","2025-11-25",{"date":91,"type":38},"2025-12-02",{"date":93,"type":38},"2023-03-07",{"date":95,"type":20},"2029-10",{"name":97,"class":45},"Cancer Research UK",27,{"id":100,"slug":101,"hasResults":11,"nctId":102,"briefTitle":103,"officialTitle":103,"acronym":104,"eligibilityCriteria":105,"healthyVolunteers":11,"sex":106,"minAge":107,"maxAge":4,"enrollmentInfo":108,"targetDuration":4,"studyType":21,"phases":110,"briefSummary":111,"conditions":112,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":116,"lastUpdatePostDateStruct":117,"startDateStruct":119,"completionDateStruct":121,"leadSponsor":123,"locationsCount":125},"100519636","clinical-genetic-and-environmental-determinants-of-prostate-cancer-progression-100519636","NCT06046131","Clinical, Genetic and Environmental Determinants of Prostate Cancer Progression.","KP-CARAIBES","Inclusion Criteria:\n\nInclusion criteria:\n\nAdult patients with incident case of prostate cancer Patient consulting the University Hospital of Guadeloupe or the University Hospital of Rennes Patient who resides in the departments of Guadeloupe or Martinique or the community of Saint-Martin or in Britany Patient affiliated or beneficiary of the social security signed consent\n\nExclusion Criteria:\n\nPhysical or mental health judjed by the investigator as precluding participation in the research Protected adults (guardianship, curatorship, safeguard of justice).","MALE","18 Years",{"count":109,"type":20},3000,[23],"The course and progression of prostate cancer is highly variable, depending on the individual characteristics, the aggressiveness of the disease at the time of diagnosis as well as the ethno-geographic origins of the individuals. The general objective of the project is to identify the clinical, genetic and environmental determinants (risk factors) of the evolution, progression and complications of the disease according to the treatment options. Identifying modifiable and non-modifiable prognostic determinants of disease progression is a major challenge. This knowledge will help guide treatment choices but also, especially in high-risk populations (high incidence of disease) to better tailor prevention policies and possibly screening .",[27,113,114,115],"Adenocarcinoma","Neoplasm Recurrence","Neoplasm Metastasis","2025-11-14",{"date":118,"type":38},"2025-11-17",{"date":120,"type":38},"2023-02-28",{"date":122,"type":20},"2039-02-28",{"name":124,"class":45},"Centre Hospitalier Universitaire de la Guadeloupe",2,{"id":127,"slug":128,"hasResults":11,"nctId":129,"briefTitle":130,"officialTitle":131,"acronym":132,"eligibilityCriteria":133,"healthyVolunteers":134,"sex":106,"minAge":107,"maxAge":4,"enrollmentInfo":135,"targetDuration":4,"studyType":21,"phases":137,"briefSummary":138,"conditions":139,"keywords":147,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":154,"lastUpdatePostDateStruct":155,"startDateStruct":157,"completionDateStruct":159,"leadSponsor":161,"locationsCount":46},"100596956","phase-3-psma-pet-combined-with-mri-for-the-detection-of-pca-100596956","NCT07052214","PSMA PET Combined With MRI for the Detection of PCa","A Single Arm, Multicenter, Prospective, Open Label, Longitudinal Phase 3 Study of Prostate Specific Membrane Antigen (PSMA) Positron Emission Tomography (PET) Combined With Magnetic Resonance Imaging (MRI) Compared to Standard of Care (SOC) for the Detection of Prostate Cancer (PCa).","BiPASS","Inclusion Criteria:\n\n1. Male, at least 18 years old.\n2. Have a clinical suspicion of PCa, and will undergo template biopsy, based on either: an initial MRI examination (PI-RADS 3-4) within 3 months (92 days) before enrollment, or no MRI evidence (PI-RADs 1-2) within 3 months (92 days) before enrollment, but a clinician indicated intent to proceed with template biopsy due to non-imaging risk factors.\n\nThese are non-imaging risk factors that would lead a patient to be considered for a template biopsy (including but not exclusive to):\n\n1. Persistently elevated or rising PSA i. PSA ≥ 3.0 ng\u002FmL ii. Rising PSA velocity (e.g., \\>0.35-0.75 ng\u002FmL\u002Fyear over 2-3 years) is also considered suspicious, especially in men with PSA\\\u003C10ng\u002FmL.\n2. High PSA density (PSAD) i. PSA density \\> 0.15 ng\u002FmL\u002Fcm³ is considered high-risk for csPCa. ii. Calculated as PSA (ng\u002FmL) divided by prostate volume (from MRI).\n3. Abnormal digital rectal examination (DRE) i. abnormal findings include:\n\n   1. Nodules\n   2. Induration\n   3. Asymmetry\n   4. Fixation of the prostate ii. An abnormal DRE in any PSA range (including \\\u003C3 ng\u002FmL) increases cancer suspicion.\n\nb) Strong family history of prostate cancer: i. First-degree relative (father or brother) with PCa ii. Any relative diagnosed at \\\u003C65 years of age iii. Multiple affected relatives iv. Known hereditary cancer syndromes (e.g., BReast CAncer gene \\[BRCA\\]1\u002F2, Homeobox protein Hox-B13 \\[HOXB13\\] mutations) c) Other high-risk biomarkers i. 4Kscore: ≥ 7.5-10% risk of high-grade PCa ii. PHI (Prostate Health Index): ≥ 35 suggests elevated risk iii. Prostate Cancer Antigen 3 (PCA3) Score: ≥ 35 considered positive and associated with increased risk of PCa.\n\niv. Any other established biomarker with values in the high-risk range d) Clinical presentation i. Symptoms suggestive of locally advanced disease (e.g., urinary obstruction, bone pain) ii. Prior negative MRI with ongoing clinical concern 3. Prostate biopsy naïve participants. 4. Eastern Cooperative Oncology Group performance status (ECOG PS) ≤2 per FDA guidelines. 5. Have the capacity to understand the study and be able and willing to comply with all protocol requirements. 6. Provides consent for anatomical template with\u002Fwithout targeted biopsy based on clinical risk, MRI and PSMA PET result. 7. Participants must comply with the radiation protection rules (including hospital admissions and isolation) that are used by the treating institution to protect their contacts and the general public, especially if a female partner of the participant is or could be pregnant.\n\n8\\. Must agree to practice adequate precautions to prevent pregnancy in a female partner and to avoid potential problems associated with radiation exposure to the unborn child (Recommendations related to contraception and pregnancy testing in clinical trials Version 1.1, (CTFG \\[Clinical Trial Facilitation Group\\], 2020). Details of contraceptive measures to be taken by male participants and their female partners are described in Appendix 4 of the Protocol.\n\nExclusion Criteria:\n\nParticipants are excluded from the study if any of the following criteria apply:\n\n1. Has had prior treatment for PCa or prior diagnosis of csPCa.\n2. Obvious metastatic disease on prior conventional imaging.\n3. Previous diagnosis of cancer of any primary origin (excluding basal cell carcinoma or squamous cell carcinoma of the skin that has undergone potentially curative therapy).\n4. Active prostate infection, or urinary test results suggestive of an active urinary tract infection, evident on medical history, within 4 weeks of enrollment.\n5. Prior pelvic irradiation\n6. Demonstrate radiographic findings of PI-RADS 5.\n7. Has abnormalities in physical examination and protocol-specified clinical laboratory tests during the Screening Period that, in the judgment of the investigator, could affect safety or compliance; and\u002For is deemed not suitable for participating in this trial in the opinion of the investigator.\n8. Unable to understand or is unwilling to sign a written informed consent document or to follow investigational procedures in the opinion of the investigator.\n9. Is unable to attain or remain in a supine position while a PET\u002FCT scan is being performed or unable to tolerate a PET\u002FCT scan\n10. Unable or unwilling to undergo clinical prostate biopsy, has known allergies, hypersensitivity, or intolerance to the investigational drug\u002Fcomparator or its excipients.\n11. Have prior use of radionuclides with an interval of less than 10 effective half-lives before the administration of 68Ga-PSMA-11.\n12. Is participating or plans to participate in any experimental drug or device trial during the study period that are considered outside of therapeutic SOC. Studies involving modifications of sequencing or timing of therapeutic regimens\u002Finterventions would be deemed eligible to enroll",true,{"count":136,"type":20},204,[60],"This is an open label, longitudinal Phase 3 study of prostate specific membrane antigen (PSMA) positron emission tomography (PET) combined with magnetic resonance imaging (MRI) compared to standard of care (SOC) for the detection of prostate cancer (PCa).",[140,26,27,141,142,143,144,145,146],"PCA","PSMA PET","Diagnostic Imaging","Elevated PSA","Positron Emission Tomography","Prostate Biopsy","Carcinoma of the Prostate",[148,149,32,33,150,151,152,153],"Molecular Imaging","Biopsy Naive","Targeted Biopsy","Radiopharmaceuticals","Cancer Detection","Urologic Oncology","2025-09-03",{"date":156,"type":38},"2025-09-10",{"date":158,"type":38},"2025-08-18",{"date":160,"type":20},"2026-11",{"name":162,"class":163},"Telix Pharmaceuticals (Innovations) Pty Limited","INDUSTRY",{"id":165,"slug":166,"hasResults":11,"nctId":167,"briefTitle":168,"officialTitle":169,"acronym":4,"eligibilityCriteria":170,"healthyVolunteers":11,"sex":106,"minAge":107,"maxAge":171,"enrollmentInfo":172,"targetDuration":4,"studyType":21,"phases":174,"briefSummary":175,"conditions":176,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":177,"lastUpdatePostDateStruct":178,"startDateStruct":180,"completionDateStruct":182,"leadSponsor":184,"locationsCount":46},"100520691","impact-of-augmented-reality-during-robot-assisted-radical-prostatectomy-100520691","NCT06059859","Impact of Augmented Reality During Robot-assisted Radical Prostatectomy","A Phase III Prospective Randomized Trial to Evaluate the Impact of Augmented Reality During Robot-assisted Radical Prostatectomy on the Rates of Postoperative Surgical Margins","Inclusion Criteria:\n\nUntreated, biopsy-proven adenocarcinoma of the prostate Age ≥18 years\n\nEuropean Association of Urology (EAU) low or intermediate risk prostate cancer:\n\n* PSA≤20 ng\u002Fml\n* cT≤2b\n* International Society for Urological Pathology \\[ISUP\\] grade group≤III Written informed consent provided for participation in the trial International Index of Erectile Function-5 (IIEF-5)≥20 No contraindications for multiparametric magnetic resonance imaging (mpMRI)\n\nExclusion Criteria:\n\nAny prior therapy for prostate cancer\n\nEuropean Association of Urology (EAU) high risk prostate cancer:\n\n* PSA\\>20 ng\u002Fml or\n* cT\\>2b or\n* ISUP grade group\\>III International Index of Erectile Function-5 (IIEF-5)\\\u003C20 Prostate cancer with sarcomatoid or spindle cell or neuroendocrine small cell components Morbidity that would limit compliance with study protocols Controindications to perform mpMRI","70 Years",{"count":173,"type":20},318,[23],"Accurate preservation of neuro-vascular bundles is crucial in guaranteeing erectile function recovery after robot assisted radical prostatectomy (RARP). However, the nerve sparing approach is associated with higher rates of positive surgical margins (PSM) at final pathology. Augmented reality (AR) RARP was previously associated with a 10-15% reduction in the rates of PSMs in two retrospective series. However, prospective studies are needed to demonstrate clinical utility and to validate these technologies. The hypotheses of this study are that: 1) AR RARP reduces the rates of PSMs, if compared to standard approach; 2) AR RARP can guarantee a more accurate preservation of neurovascular bundles and, in consequence, a greater recovery of erectile function; 3) the lower rates of PSMs will translate in greater oncological control of the disease.",[27],"2025-08-07",{"date":179,"type":38},"2025-08-12",{"date":181,"type":38},"2022-01-01",{"date":183,"type":20},"2026-01-01",{"name":185,"class":45},"European Institute of Oncology",{"id":187,"slug":188,"hasResults":11,"nctId":189,"briefTitle":190,"officialTitle":191,"acronym":192,"eligibilityCriteria":193,"healthyVolunteers":11,"sex":106,"minAge":194,"maxAge":195,"enrollmentInfo":196,"targetDuration":198,"studyType":199,"phases":4,"briefSummary":200,"conditions":201,"keywords":208,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":214,"lastUpdatePostDateStruct":215,"startDateStruct":217,"completionDateStruct":219,"leadSponsor":221,"locationsCount":46},"100449217","prostate-cancer-genetic-risk-evaluation-and-screening-study-100449217","NCT05129605","Prostate Cancer Genetic Risk Evaluation and Screening Study","Prostate Cancer Genetic Risk Evaluation and Screening Study (PROGRESS)","PROGRESS","Inclusion Criteria:\n\n* Men 35-74 years old\n* No known diagnosis of prostate cancer\n* Life expectancy \\>10 years\n* Meet cohort A, B, or C criteria\n* Cohort A: Documented pathogenic or likely pathogenic germline genetic mutation in a prostate cancer risk gene from a CLIA-certified laboratory (ATM, ATR, BRCA1, BRCA2, BRIP1, CHEK2, EPCAM, FANCA, GEN1, HOXB13, MLH1, MSH2, MSH6, NBN, PALB2, PMS2, RAD51C, RAD51D, TP53)\n* Cohort B: A strong family history suggestive of high genetic risk for prostate cancer with negative clinical genetic testing\n* Cohort C: Individuals who self-identify as Black American or Black Caribbean with both parents and all four grandparents of Black\u002FAfrican ancestry\n\nExclusion Criteria:\n\n* Prior diagnosis or treatment of prostate cancer\n* Inability to undergo prostate MRI\n* Inability to receive MRI contrast agent","35 Years","74 Years",{"count":197,"type":20},400,"10 Years","OBSERVATIONAL","This study aims to define the natural history of men at high genetic risk for prostate cancer on the basis of specific germline genetic mutations, family history, or Black\u002FAfrican ancestry and evaluate the utility of prostate MRI as a screening tool. The hypothesis is that this targeted population of men are at elevated risk of developing prostate cancer compared to the general population, and enhanced screening with MRI will enable early detection and diagnosis of potentially aggressive prostate cancer, characterization of the penetrance of specific mutations, and potentially identify new genetic risk mutations.",[27,26,202,203,204,205,206,207],"BRCA2 Mutation","BRCA1 Mutation","ATM Gene Mutation","MMR Mutation","Lynch Syndrome","Genetic Predisposition to Disease",[209,210,211,206,212,213],"BRCA2","BRCA1","Mismatch Repair Deficiency","HOXB13","Family History of Prostate Cancer","2024-10-05",{"date":216,"type":38},"2024-10-09",{"date":218,"type":38},"2020-02-12",{"date":220,"type":20},"2040-12",{"name":222,"class":45},"Massachusetts General Hospital",{"id":224,"slug":225,"hasResults":11,"nctId":226,"briefTitle":227,"officialTitle":228,"acronym":229,"eligibilityCriteria":230,"healthyVolunteers":11,"sex":106,"minAge":107,"maxAge":4,"enrollmentInfo":231,"targetDuration":4,"studyType":199,"phases":4,"briefSummary":233,"conditions":234,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":238,"lastUpdatePostDateStruct":239,"startDateStruct":241,"completionDateStruct":243,"leadSponsor":245,"locationsCount":46},"100538596","using-tissue-based-spatial-data-to-understand-how-obesity-related-tumor-metabolites-fuel-prostate-cancer-progression-100538596","NCT06292897","Using Tissue-based Spatial Data to Understand How Obesity-related Tumor Metabolites Fuel Prostate Cancer Progression","Integrating Tissue-based Spatial Information to Elucidate How Obesity-induced Tumour Metabolites Drive Prostate Cancer Progression","OBESITA'&PCa","Inclusion Criteria:\n\n* affected by prostate cancer\n\nExclusion Criteria:\n\n\\-",{"count":232,"type":20},25,"Evaluate the protein expression of lactate dehydrogenase enzyme (LDHA) and MCT-1\u002F-4 transporters, involved in lactate synthesis and transport, in prostate carcinoma tissues from severely overweight\u002Fobese (BMI \\> 27.5) and non-severely overweight\u002Fnormoweight (BMI \\\u003C 27.5) patients affected by prostate carcinoma.\n\nii. Characterize the immune infiltrate in the prostate carcinoma of the aforementioned patients.\n\niii. Assess the association between intra-tumoral lactate accumulation (using LDHA and MCT-4 protein expression levels as readouts) and alterations in the tumor immune microenvironment and\u002For deregulation of relevant oncogenic pathways.",[26,235,236,27,237],"Prostate Adenocarcinoma","Prostate Neoplasm","Obesity","2024-02-27",{"date":240,"type":38},"2024-03-05",{"date":242,"type":38},"2023-03-20",{"date":244,"type":20},"2027-01-15",{"name":246,"class":45},"Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico",{"id":248,"slug":249,"hasResults":11,"nctId":250,"briefTitle":251,"officialTitle":4,"acronym":4,"eligibilityCriteria":252,"healthyVolunteers":11,"sex":106,"minAge":253,"maxAge":4,"enrollmentInfo":254,"targetDuration":4,"studyType":199,"phases":4,"briefSummary":256,"conditions":257,"keywords":258,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":263,"lastUpdatePostDateStruct":264,"startDateStruct":266,"completionDateStruct":268,"leadSponsor":269,"locationsCount":46},"100534281","observation-study-to-evaluate-the-efficacy-and-safety-of-ifosfamidemesna-in-patients-with-metastatic-castration-resistant-prostate-cancer-100534281","NCT06236789","Observation Study to Evaluate the Efficacy and Safety of Ifosfamide\u002FMesna in Patients With Metastatic Castration-resistant Prostate Cancer","Inclusion Criteria:\n\n1. 19 years and older adult male\n2. Patients with histologically confirmed prostate cancer\n3. Castration-resistant prostate cancer\n4. ECOG 2 or less\n5. Patients with previous docetaxel exposure\n6. Patients with available PSA level\n7. Patients with evaluable disease based on RECIST 1.1\n\nExclusion Criteria:\n\n1. Patients with other primary cancers diagnosed within 3 years other than prostate cancer\n2. Patients with a history of organ transplantation\n3. Hormone sensitive prostate cancer\n4. ECOG 3 or higher\n5. Patients without previous docetaxel exposure\n6. Patients previously exposed to ifosfamide\n7. Patients without available PSA level\n8. Patients without evaluable disease based on RECIST 1.1","19 Years",{"count":255,"type":20},60,"Prostate cancer is the 2nd most common cancer in men worldwide. Based on the results of several recent clinical trials, systemic treatments including hormone inhibitors, docetaxel, cabazitaxel, and PARP inhibitors are being used as standard treatment for patients with metastatic castration-resistant prostate cancer. However, there is insufficient research on salvage therapy for patients with metastatic castration-resistant prostate cancer who have failed standard treatment. In this study, the investigators will evaluate the effectiveness and safety of ifosfamide in castration-resistant prostate cancer by analyzing the treatment outcomes of patients who received ifosfamide\u002Fmesna treatment as salvage therapy.",[27],[259,260,261,262],"Castration-resistant prostate cancer","Ifosfamide\u002Fmesna","Efficacy","Safety","2024-01-24",{"date":265,"type":38},"2024-02-01",{"date":267,"type":38},"2016-11",{"date":160,"type":20},{"name":270,"class":45},"Yonsei University"]